14658-93-6

Basic information

• Product Name: acetamide, 2-hydroxy-N,N-dimethyl-
• Synonyms: 2-hydroxy-N,N-dimethylacetamide;acetamide, 2-hydroxy-N,N-dimethyl-;2-hydroxy-N,N-dimethylacetamide(SALTDATA: FREE);2-hydroxy-N,N-dimethyl-ethanamide
• CAS NO: 14658-93-6
• Molecular Formula: C₄H₉NO₂
• Molecular Weight: 103.11976
• Mol File: 14658-93-6.mol

Chemical Properties

• Melting Point: 43-45.5 °C
• Boiling Point: 90 °C(Press: 0.5 Torr)
• Appearance: /
• Density: 1.069±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• PKA: 13.28±0.10(Predicted)
• CAS DataBase Reference: acetamide, 2-hydroxy-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: acetamide, 2-hydroxy-N,N-dimethyl-(14658-93-6)
• EPA Substance Registry System: acetamide, 2-hydroxy-N,N-dimethyl-(14658-93-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 14658-93-6(Hazardous Substances Data)

Usage

Uses

Used in Dietary Supplements:
Acetamide, 2-hydroxy-N,N-dimethylis used as a dietary supplement for enhancing physical performance and boosting the immune system.
Used in Industrial Processes:
Acetamide, 2-hydroxy-N,N-dimethylis used as a solvent in various industrial processes due to its chemical stability and high boiling point.
Used in Environmental Considerations:
Acetamide, 2-hydroxy-N,N-dimethylis used in the context of environmental considerations due to its distinct odor, which may impact its use in certain applications.
Used in Safety Precautions:
Acetamide, 2-hydroxy-N,N-dimethylis used with caution in safety precautions due to its potentially harmful effects when inhaled, ingested, or exposed to skin.

Upstream product

• 96-35-5 glycolic acid methyl ester 
• 124-40-3 dimethyl amine 
• 19374-87-9 (2,5-dioxopyrrolidin-1-yl) 2-hydroxyacetate 
• 7397-62-8 butyl glycolate 
• 1608-14-6 N,N,N'N'-tetramethyl oxamide 
• 30379-55-6 benzyloxyacetic acid 
• 623-50-7 ethyl 2-hydroxyacetate 
• 41858-11-1 2-benzyloxy-N,N-dimethylacetamide 
• 59721-29-8 camostat mesylate 
• 106231-54-3 2-(dimethylamino)-2-oxoethyl benzoate 
• 502-97-6 glycolide 

Downstream Products

• 1259039-83-2 2-(dimethylamino)-2-oxoethyl (3S)-2-(4-{[bis(1H-imidazol-2-ylmethyl)amino]methyl}benzyl)-8-(2,2-dimethylpropyl)-2,8-diazaspiro[4.5]decane-3-carboxylate 
• 1327238-88-9 2-(cyclohexyloxymethoxy)-N,N-dimethylacetamide 
• 930604-22-1 dimethylcarbamoylmethyl 1'-{(R)-3-(4-benzyloxy-3,5-dimethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]propionyl}-1,4'-bipiperidinyl-4-carboxylate 
• 118635-52-2 N,N-dimethylcarbamoylmethyl α,2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetate 
• 410544-83-1 Methyl 8-(benzoyloxy)-5-[2-(dimethylamino)-2-oxoethoxy][1,6]-naphthyridine-7-carboxylate 

Relevant articles and documents

Synthesis and biological activity of novel ester derivatives of N3-(4-metoxyfumaroyl)-(S)-2,3-diaminopropanoic acid containing amide and keto function as inhibitors of glucosamine-6-phosphate synthase

A short series of novel ester derivatives of N3-4-metoxyfumaroyl-(S)-2,3-diaminopropanoic acid (FMDP) containing amide or keto functions have been designed and synthesized. Their antifungal activity and inhibitory properties toward fungal glucosamine-6-phosphate synthase has also been evaluated. The obtained compounds 11–13 and 15–17 demonstrated good antifungal activity against Candida albicans. Compounds 11–13 displayed also potent inhibitory activity against fungal glucosamine-6-phosphate synthase, comparable to that of FMDP.

NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. The cyclic amine derivative is represented by formula, a prodrug thereof or a pharmacologically acceptable salt thereof: wherein A represents a group represented by Formula (IIa), (IIb) or (IIc): wherein R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R4 represents a hydrogen atom or an alkylcarbonyl group having 2 to 6 carbon atoms or an alkyl group having 1 to 6 carbon atoms and optionally substituted with an alkylcarbonylamino group having 2 to 6 carbon atoms and n represents 1 or 2, in which when R3 and R4 each independently represent an alkyl group having 1 to 6 carbon atoms, R1 represents an alkyl group having 1 to 6 carbon atoms and substituted with a hydroxyl group, an amino group or a carboxyl group.

Cyclic amine derivative and pharmaceutical use thereof

The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine derivative represented by chemical formula, a prodrug thereof or a pharmaceutically acceptable salt thereof.

MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS

This invention relates macrocyclic purine derivatives having formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Expanded substrate scope and improved reactivity of ether-forming cross-coupling reactions of organotrifluoroborates and acetals

Mixed acetals and organotrifluoroborates undergo BF3· OEt2-promoted cross-couplings to give dialkyl ethers under simple, mild conditions. A survey of reaction partners identified a hydroxamate leaving group that improves the regioselectivity and product yield in the BF 3·OEt2-promoted coupling reaction of mixed acetals and potassium alkynyl-, alkenyl-, aryl- and heteroaryltrifluoroborates to access substituted dialkyl ethers. This leaving group enables the reaction to proceed rapidly under mild conditions (0 °C, 5-60 min) and permits reactions with electron-deficient potassium aryltrifluoroborates that are less reactive with other acetal substrates. A study of the reaction mechanism and characterization of key intermediates by NMR spectroscopy and X-ray crystallography identified a role for the hydroxamate moiety as a reversible leaving group that serves to stabilize the key oxocarbenium intermediate and the need for a slight excess of organodifluoroborane to serve as a catalyst. A secondary role for the boron nucleophile as an activating ligand was also considered. These studies provide the basis for a general class of reagents that lead to dialkyl ethers by a simple, predictable cross-coupling reaction.

PROCESS FOR THE PRODUCTION OF ETHYLENE GLYCOL AND RELATED COMPOUNDS

The present invention provide a process for the production of compounds of general formula (I), Y-CH2CH2-Z (I) wherein Y and Z are functional groups independently selected from the group consisting of a hydroxyl group and R1R2N and wherein R1 and R2 may be the same or different and are functional groups selected from the group consisting of hydrogen and substituted or non- substituited alkyl groups comprising 1 to 8 carbon atoms, or R1R2N is a cyclic compound selected from the group of aromatic and non-aromatic cyclic compounds optionally comprising one or more heteroatoms in addition to the nitrogen atom, said process comprising the steps of: (i) reacting carbon monoxide and an amine in the presence of oxygen to provide a compound of general formula (II) wherein R1 and R2 or R1R2N are as defined above and X is selected from the group consisting of R1R2N and R3O, wherein R3 is selected from alkyl groups comprising 1 to 8 carbon atoms; and (ii) converting the compound of general formula (II) into a compound of general formula (I) by a process that comprises a hydrogenation reaction.

Dehydrative sialylation with C2-hemiketal sialyl donors

(Matrix presented) A new method for sialylation involving the dehydrative coupling of sialyl donors with the reagent combination of (p-nitrophenyl)(phenyl) sulfoxide and triflic anhydride is reported. This process establishes sialyl C2-hemiketals as viabl

Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver

Carboxylesterases (EC 3.1.1.1) from human liver were purified using Q- Sepharose, Sephadex G-150, isoelectrofocusing and Con A-Sepharose. The calculated molecular mass of the pI 5.3 enzyme was 120 kDa and 61 kDa from the results of Sephadex G-150 gel filtration and SDS-polyacrylamide gel electrophoresis (PAGE), respectively, suggesting that this enzyme is a dimer. On the other hand, carboxylesterase pI 4.5, with a molecular-mass of 64 kDa, was a monomer. The activities of both enzymes were inhibited by typical serine enzyme inhibitors. Amino acid sequence analysis of the purified enzymes pI 5.3 and 4.5 showed high homology with rabbit carboxylesterase form 1 and 2, respectively. The results also suggested that carboxylesterase pI 5.3 is identical to the deduced amino acid sequence from cDNA for HUI, and that carboxylesterase pI 4.5 is identical to the deduced amino acid sequence from the cDNA registered as human carboxylesterase (hCE-2) in GenBank. We first purified carboxylesterase pI 4.5 and investigated its hydrolytic activity upon various drugs. The two enzymes differed in substrate specificity. Prodrugs of angiotensin-converting enzyme inhibitors, such as delapril and imidapril, were converted to active metabolites by carboxylesterase pI 5.3, but not by carboxylesterase pI 4.5. The hydrolysis velocity of temocapril by carboxylesterase pI 5.3 was 12-fold faster than by carboxylesterase pI 4.5. In contrast, aspirin oxybutynin and procaine were hydrolyzed by only carboxylesterase pI 4.5. We also found that an amide- linkage in drugs, except for that in aniracetam was not a good substrate for the two enzymes. Consequently, carboxylesterases pI 5.3 and 4.5 maybe involved in the metabolism of various drugs containing an ester-linkage.

Imidazole derivatives and their use as cytokine inhibitors

As cytokine inhibitors 2,4,5-triarylimidazole compounds and compositions for use as cytokine inhibitors.